Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Challenges of Implementing and Validating CTC Assays in Oncology Clinical Trials
Iman Jilani, Pfizer, speaking at Exosomes and Circulating Biomarkers Summit 2013.
Date Posted: Sunday, March 30, 2014
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®
Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.
Thursday, April 09, 2015
Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer, Merck to Evaluate Novel Anti-Cancer Combination Regimen
This multi-center, open-label clinical study will be conducted by Pfizer and is expected to begin in 2015.
Wednesday, August 27, 2014
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Plan for Split-Off of Zoetis
The offer better positions Pfizer to focus on its core business as an innovative biopharmaceutical company.
Thursday, May 23, 2013
Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.
Tuesday, March 05, 2013
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Announces Positive Results From Phase 3 Cancer Study
Study PROFILE 1007 evaluates XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer.
Wednesday, June 27, 2012
Pfizer Maneuvers to Protect Lipitor from Generics
Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hit the U.S. market last week.
Tuesday, December 06, 2011
Pfizer to Acquire Icagen
Pfizer Inc. and Icagen, Inc. announce that they have entered into a definitive merger agreement.
Thursday, August 04, 2011
Pfizer and Samsung Medical Center Collaborate on Liver Cancer
Collaboration aims to conduct joint research to identify genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma.
Friday, July 16, 2010
Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.
Tuesday, June 15, 2010
Scientific News
Finding Points To A Cause Of Chronic Lung Disease
New research explains how macrophages in the lung sometimes stick around too long, even after clearing a viral infection, leading to long-term lung problems.
A New Wrinkle For Cell Culture
Researchers at Brown University have developed an advanced technique for cell culturing that uses sheets of wrinkled graphene to mimic the complex 3-D environment inside the body.
Twins Experiment Reveals Genetic Link with Mosquito Bites
Findings show that attractiveness to insects is based on differences in body odor.
Detecting Cryptosporidium in China
A recently developed lab-on-a-chip device, which can diagnose the opportunistic parasite in as little as 10 minutes, may help improve treatment in remote, at-risk rural areas.
Quotient Clinical Completes Innovative First-In-Human Program
First-in-human clinical program designed to develop an optimal oral formulation.
Detecting Low-Quality Antimalarial Drugs With A Lab-On-Paper
Lab-on-Paper can detect low-quality anitmalarial drugs without expensive equipment.
A New Lease on Life for Prostate Tissue
Rutgers Cancer Institute of New Jersey research results in development of organoid prostate models
Imaging Immunity
Noninvasive imaging of immune system detects tumors, could monitor therapeutic response.
First Atlas Of Airborne Microbes Across US
Bacteria and fungal species were identified from outdoor dust samples collected from all 50 states.
Measuring Volumes of Key 'Lab on a Chip' Components
NIST found a combination of techniques to effectively measure microfluidic channels, achieving an accuracy of within 5 percent for both a channel's depth and its bottom's width.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters